Physician profile
Amy Chen
NPI 1164681573
$8,295.47
in general payments reported to CMS, 2019-2025
26 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $796 · 2021: $1,492 · 2022: $994 · 2023: $906 · 2024: $1,191 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,855.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,786.09 | 2019-2025 | Rinvoq, Botox, Skyrizi |
| Pfizer INC. | $1,195.83 | 2019-2025 | |
| Janssen Biotech, INC. | $1,083.52 | 2019-2025 | Tremfya |
| Genzyme Corporation | $476.00 | 2020-2025 | |
| Lilly USA, LLC | $374.47 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $351.96 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $308.97 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Leo Pharma INC. | $291.56 | 2019-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $288.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $268.43 | 2019-2022 | |
| Dermavant Sciences, INC. | $250.81 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $203.58 | 2019-2022 | |
| Epi Health, LLC | $196.05 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $177.04 | 2019-2021 | |
| Amgen INC. | $172.34 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $157.34 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $142.48 | 2022-2025 | Nemluvio |
| Incyte Corporation | $139.82 | 2021-2022 | |
| Ucb, INC. | $112.26 | 2019-2025 | Bimzelx |
| Allergan, INC. | $95.75 | 2022 | |
| Dermira, INC. | $67.56 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $48.00 | 2019 | |
| Nobelpharma America, LLC | $40.90 | 2025 | |
| Encore Dermatology INC. | $25.99 | 2019 | |
| Vyne Pharmaceuticals INC. | $23.33 | 2020 | |
| Celgene Corporation | $17.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.